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Abstract. Malarial infection and curable sexually transmitted and reproductive tract infections (STIs/RTIs) are
important causes of adverse birth outcomes. Reducing the burden of these infections in pregnancy requires interven-
tions that can be easily integrated into the antenatal care (ANC) package. However, efforts to integrate the control
of malarial infection and curable STIs/RTIs in pregnancy have been hampered by a lack of evidence related to their
coinfection. Thus, we investigated the prevalence of coinfection among pregnant women of rural Zambia. A prospec-
tive cohort study was conducted in Nchelenge District, Zambia, involving 1,086 first ANC attendees. We screened
participants for peripheral malarial infection and curable STIs/RTIs (syphilis, Chlamydia, gonorrhea, trichomoniasis,
and bacterial vaginosis), and collected relevant sociodemographic data at booking. Factors associated with malarial
and STI/RTI coinfection were explored using univariate and multivariate regression models. Among participants
with complete results (N = 1,071), 38.7% (95% confidence interval [CI] = 35.7–41.6) were coinfected with malaria
parasites and at least one STI/RTI; 18.9% (95% CI = 16.5–21.2) were infected with malaria parasites only; 26.0%
(95% CI = 23.5–28.8) were infected with at least one STI/RTI but no malaria parasites, and 16.4% (95% CI = 14.1–18.6)
had no infection. Human immunodeficiency virus (HIV)-infected women had a higher risk of being coinfected than
HIV-uninfected women (odds ratio [OR] = 3.59 [95% CI = 1.73–7.48], P < 0.001). The prevalence of malarial and
STI/RTI coinfection was high in this population. An integrated approach to control malarial infection and STIs/RTIs
is needed to reduce this dual burden in pregnancy.
INTRODUCTION
Maternal malarial infection and sexually transmitted and
reproductive tract infections (STIs/RTIs) are important causes
of adverse birth outcome in sub-Saharan Africa. Malarial
infection in pregnancy is associated with intrauterine growth
retardation,1,2 preterm delivery,2,3 stillbirth,4 and low birth
weight.2,5 Syphilis,4 Chlamydia,6–10 gonorrhea,6,9,11 trichomoni-
asis,12,13 and bacterial vaginosis14–16 have also been associated
with adverse birth outcomes. To reduce the burden of malar-
ial infection in areas of moderate (stable)-to- high transmis-
sion, the World Health Organization (WHO) recommends
providing intermittent preventive treatment in pregnancy
using sulfadoxine-pyrimethamine (IPTp-SP) at all scheduled
antenatal care (ANC) visits from the second trimester to deliv-
ery.17 Despite a decade since the WHO first recommended
IPTp-SP,18 coverage remains disappointingly low in sub-Saharan
Africa. The average coverage of at least two doses of IPTp-
SP among pregnant women in 2013 was 24%, only slightly
higher than a decade earlier when coverage was 14%.19 The
efficacy of IPTp-SP has been undermined by the emergence
of SP-resistant parasites20 and the effectiveness of three doses
of IPTp-SP may be suboptimal in areas with very high SP
resistance.21 Thus, there is need to identify alternative drugs
for IPTp in areas where parasites have lost SP sensitivity.
Antenatal syphilis screening is a standard policy through-
out sub-Saharan Africa. A recent meta-analysis, however,
estimated that only 39.5% of pregnant women throughout
the region were screened during ANC visits.22 Other curable
STIs/RTIs are diagnosed during ANC consultations using
syndrome-based algorithms recommended by the WHO.23
However, the algorithms have poor sensitivity among preg-
nant women for detecting Chlamydia, gonorrhea, trichomo-
niasis, and bacterial vaginosis.24 Therefore, a considerable
burden of curable STIs/RTIs remains undetected and untreated
in pregnancy.
A systematic review and meta-analysis of 171 studies
showed that the prevalence of malarial infection and curable
STIs/RTIs is unacceptably high among pregnant women
attending ANC facilities in sub-Saharan Africa.25 This analysis
also highlighted the paucity of data on the frequency of
malarial and curable STI/RTI coinfection (syphilis, Chlamydia,
gonorrhea, trichomoniasis, and bacterial vaginosis).25 In the
context of increasing malaria parasite resistance to SP, particu-
larly in east and southern Africa, and the limited diagnostic
precision of the syndromic management among pregnant
women, new strategies to control these infections in pregnancy
are needed. One option under consideration is to provide
combination therapy that is safe and effective against malarial
infection and curable STIs/RTIs.26 Quantifying the prevalence
of malarial and STI/RTI coinfection is an important step
toward tailoring integrated interventions. Thus, we conducted
a prospective cohort study to estimate the prevalence of
malarial infection, curable STIs/RTIs, and their coinfection in
pregnant women and their effects on pregnancy outcomes.
We provide evidence of the frequency of coinfection among
pregnant women who present at ANC and the effect of HIV
infection on the prevalence of malarial and STI/RTI coinfec-
tion. We also explore predictors of malarial and STI/RTI
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coinfection and assess whether there is an association between
coinfection and adverse birth outcomes.
METHODS
The study setting and sample size calculations have been
described elsewhere.27 Briefly, the study site was the catch-
ment area for two health centers, Nchelenge and Kashikishi,
in Nchelenge District, which is located on the shores of Lake
Mweru, northern Zambia, and has a population of 173,680.28
We invited women to participate in the study from two health
centers at ANC booking. Pregnant women (N = 1,086) were
enrolled if they provided informed written consent, stated
they had not been exposed to anti-malarial and/or antibiotic
therapy within the previous 4 weeks, agreed to have a mem-
ber of the study team record their HIV test results follow-
ing routine HIV screening, and had a gestational age of
< 32 weeks. Study participants were screened for syphilis
using rapid plasma reagin (RPR) methods according to
national norms. Women were notified of their test results if
found to be RPR positive and referred for treatment. Screen-
ing for malarial infection and curable STIs/RTIs, apart from
syphilis, is not standard and, therefore, retrospective batch
analyses were conducted on relevant samples. Women who
had fever or any other symptoms during the antenatal period
were given care according to national norms. All women
enrolled were followed until delivery.
Sample collection and laboratory methods. Health facility
staff conducted routine HIV screening with finger-prick
blood with Determine® HIV-1/2 (Abbott Diagnostic Division,
Hoofddorp, The Netherlands) tests and confirmed positivity
using Uni-Gold™ Recombigen® HIV-1/2 (Trinity Biotech
USA Inc., New York, NY) assays. Trained field workers
administered a questionnaire to participating women in a
private room at the ANC facility to collect information on
sociodemographics, malaria infection prevention interventions,
HIV status, and obstetric history.
Study staff collected blood samples for Plasmodium
falciparum malaria diagnosis by polymerase chain reaction
(PCR). It is important to note that in Zambia, P. falciparum
is responsible for approximately 95% of all malaria cases.29
Details of the diagnostic method have been described else-
where.27 Malarial infection prevalence was defined as PCR-
detected P. falciparum parasitemia because the technique
is highly sensitive and consistent in the detection of para-
sites.30,31 For the diagnosis of vaginal and cervical infections
of interest, a trained midwife collected one vaginal swab
and one cervicovaginal swab from each participant using
nonlubricated vaginal specula. A dry cotton swab was placed
in the vaginal cavity for about 10 seconds and then immedi-
ately rolled onto a slide for use in diagnosis of bacterial vagi-
nosis. The midwife then collected a cervicovaginal sample
using a Dacron® (Medical Wire & Equipment, Wiltshire,
England, United Kingdom) swab for the detection of Chlamydia
trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis
by PCR. Each Dacron swab was placed in a cryovial (Narang
Medical Limited, New Delhi, India) with a unique identifica-
tion number that corresponded to each participant and the date
of collection. Samples were then stored at −20°C for 6–12 hours.
Within 24 hours of collection, we extracted the DNA from
cervicovaginal swabs using the Quick-gDNA™ (Zymo Research
Corp., Irvine, CA) Miniprep kit and stored the extracts at
−20°C awaiting nucleic acid amplification.
Clinic staff collected venous blood (approximately 4 mL)
from each participant for RPR analysis (Omega Diagnostics
Limited, Alva, Scotland, United Kingdom). Field workers
provided seropositive women with a note to return to the
health center accompanied by their partner for free syphilis
treatment with benzathine penicillin G (2.4 million units IM
weekly × 3 weeks). We used Treponema pallidum hemag-
glutination assay (TPHA) (Chronolab Systems, Barcelona,
Spain) to confirm syphilis infection on all RPR-seropositive
samples. For quality control, we had 5% (55/1,077) of serum
samples independently analyzed by the national STI reference
laboratory at the University Teaching Hospital in Lusaka. Of
the 117 RPR-positive samples, 30 (26%) were tested for
TPHA quality control. Vaginal smear samples for the diagno-
sis of bacterial vaginosis were air dried and Gram stained
using safranin as a counter stain. We classified results based
on the Nugent criteria.32 As with syphilis, we randomly
selected 5% (55/1,085) of slides for independent reading at the
microbiology laboratory of the University Teaching Hospital.
The extracted DNA samples were transported on dry ice
to the Tropical Gastroenterology and Nutrition Group labo-
ratory at the University Teaching Hospital, where we used
in-house standard end-point PCR assays to detect the pres-
ence of C. trachomatis, N. gonorrhoeae, and T. vaginalis
among cervicovaginal samples with PCR techniques previ-
ously described.33–35
We pretested all the PCR assays on known positive samples
before they were applied to research samples, and used posi-
tive and negative controls at the extraction, amplification, and
electrophoresis stages. A negative and a positive control were
included in every batch of 46 samples. For quality control,
we randomly selected 5% of the samples (55/1,084) and
processed them using the Seeplex® STI Master Panel 1 V2.0
(Seegene Technologies Inc., Concord, CA). The Seeplex STI
Master Panel 1 is a multiplex conventional PCR system for
the detection of seven organisms including C. trachomatis, N.
gonorrhoeae, and T. vaginalis from urine, vaginal swabs, and
liquid-based cytology specimens. At delivery, infants were
weighed and birth characteristics recorded. Stillbirth was
defined as fetal death at ≥ 28 weeks gestation,36 preterm as
delivery at < 37 weeks, low birthweight as birthweight < 2,500
g, and intra-uterine growth retardation was defined as an
infant with low birth weight born at ≥ 37 weeks gestation.2,37
Gestational age after birth was recorded based on earlier
assessment at enrolment by ultrasound.
The study protocol was approved by the University of
Zambia Biomedical Research Ethics Committee (No. 004-
02-13) and the London School of Hygiene and Tropical
Medicine Observational/Interventions Research Ethics Com-
mittee (No. 6292).
Statistical analysis. Study data were double entered and
verified in EpiData version 3.1 software,38 then cleaned,
processed, and analyzed using Stata Software version 13.39
We generated necessary composite variables prior to all data
analysis and created an index of household wealth using prin-
cipal components analysis using data on source of income,
level of education as well as fixed and durable assets.40 We
estimated the frequency distributions of baseline characteris-
tics among all study women and then stratified results first by
health center and then HIV status.
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A four-level variable was constructed to define whether a
woman was 1) coinfected, 2) had malarial infection but no
STI/RTI, 3) had only STI/RTI and no malarial infection,
4) or had no infection. The relationship between coinfection
and HIV status was examined. A χ2 test was used to assess
statistical significance of all associations.
Univariate logistic regression was used to identify poten-
tial predictors of malaria and STI/RTI coinfection, and each
variable was assessed using a likelihood ratio test. All poten-
tial predictors of coinfection which were significant at the
10% level in the univariate analysis were input into a multi-
variable model and their adjusted effect on the risk of coin-
fection estimated. Potential predictors that were found to be
independently associated with coinfection (P < 0.05) were
entered in a final model. The associations between adverse
birth outcome and malarial infection, STI/RTI and coinfec-
tion were also tested using logistic regression.
RESULTS
A total of 1,086 pregnant women were recruited between
November 2013 and April 2014, a period which spans the high
malaria transmission season. Study staff followed up partici-
pants until the last women delivered in November 2014.
Figure 1 shows a flow chart of participation distribution. Less
than 1% (N = 9) of first ANC attendees who met all other
criteria for participation refused to take part in the study. The
median age of participants was 25 (IQR [interquartile range] =
20–25) years, 61.7% were multigravidae and slightly over
80% of them were married. Sociodemographic details of
study women are presented in Table 1. Table 2 summarizes
the prevalence of malarial infection and STIs/RTIs among
study participants.
The prevalence estimates of composite and individual STI/
RTI and malarial coinfection by HIV status are shown in
Table 3. The prevalence of HIV infection among participants
was 13.2% (95% confidence interval [CI] = 11.3–15.3).
Among women who tested positive for HIV, combined with
those with known HIV-positive status, 42.7% were receiving
antiretroviral therapy at the time of recruitment. The preva-
lence of malarial and any one STI/RTI coinfection was
higher among HIV-infected (50.0%, 95% CI = 41.6–58.4%)
than HIV-uninfected women (37.0%, 95% CI = 33.9–40.1%)
with a 95% CI of the difference ranging between 3.0%
and 20.3%. The prevalence of coinfection with malaria para-
sites and each individual STI/RTI was also higher among
HIV-infected than HIV-uninfected women. However, these
differences in the prevalence between HIV-infected and
HIV-uninfected women were only statistically significant in
the cases of malarial and syphilis or bacterial vaginosis coin-
fections. The STI/RTI that coexisted the most with malarial
infection in this study population was bacterial vaginosis and
gonorrhea occurred the least with malarial infection.
In univariate logistic models, the following factors were
associated with malarial and STI/RTI coinfection at a 10%
significance level (P < 0.1): 1) age group, 2) gravidity, 3)
bed-net ownership, 4) bed-net usage, and 5) HIV status.
After adjusting for all known potential risk factors in a multi-
variable model, only HIV infection was independently asso-
ciated with malarial and STI/RTI coinfection. HIV-infected
women were at a higher risk of being coinfected with malaria
parasites and at least one curable STI/RTI compared with
FIGURE 1. Participation flowchart.
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HIV-uninfected women (odds ratio [OR] = 3.59 [95% CI =
1.73–7.48], P < 0.001) (Table 4).
Results for quality control testing were highly concordant.
There was a 96.4% (53/55) concordance in the Nugent score
results obtained from the repeat reading of slides for detec-
tion of bacterial vaginosis. The two readings both conflicted
between the normal and the intermediate class. Syphilis
RPR results were 100% (55/55) concordant; TPHA testing
was 100% (30/30) concordant. For C. trachomatis, agreement
of test results between the in-house methods and the Seeplex
STI Master Panel 1 kit was 96.4% (54/55). In the case of
N. gonorrhoeae and T. vaginalis, there was 100% concordance
between the in-house methods and the commercial kit.
Loss to follow-up in this study was much higher (33%)
than expected (10%). However, there were no differences
in the characteristics of women who were followed up to
delivery and those who were lost to follow-up. Of the 729 par-
ticipants followed to delivery, 98.4% (N = 717) had singleton
deliveries and 1.6% (N = 12) had twin deliveries. Overall, the
prevalence of adverse birth outcome among the 717 women
with singleton deliveries was 35.0% (N = 251). Among 717
singleton deliveries, preterm delivery, low birth weight, intra-
uterine growth retardation, and stillbirth were observed in
22.1% (N = 158), 21.9% (157/716), 15.2% (N = 85), and 1.7%,
(N = 12), respectively.
In the univariate analysis, women who were monoinfected
(malarial infection or at least one STI/RTI) and coinfected
had 24% and 31% increased risk of experiencing an adverse
birth outcome, respectively, compared with uninfected women,
but this was not statistically significant. We found no associa-
tion between malarial infection or STI/RTI and adverse birth
outcome in the univariate analysis as summarized in Table 5.
DISCUSSION
The estimated prevalence of malarial and curable STI/RTI
coinfection among all gravidae was considerable (38.7%;
95% CI = 35.7–41.6%). To our knowledge, there has only
been one previous study that reported the prevalence of
malarial and curable STI/RTI coinfection (syphilis only).
That was in Tanzania where 48.3% of RPR-positive women
also had placental malarial infection.25 In contrast, we found
the prevalence of malarial and syphilis coinfection to be
10.5% based on RPR testing and peripheral parasitemia
diagnosed by PCR among pregnant women at ANC book-
ing. Malarial and syphilis coinfection based on RPR and
TPHA results in this study was 4.0%. The difference in the
prevalence of malarial and syphilis (RPR-based seropositivity)
coinfection between the two studies may partially be explained
by the fact that the study in Tanzania was conducted in 1997–
2000, when malaria endemicity was higher than 2013, and
the prevalence of placental parasitemia can be higher than
peripheral parasitemia.
Although malaria parasite transmission occurs year-round,
the incidence of malaria rises during the rainy season, which
is when this study was conducted. Thus, the observed preva-
lence of malarial and STI/RTI coinfection may have been
higher than might be found during other times of the year.
The prevalence of malarial and STI/RTI coinfection may have
been influenced by the fact that some of the HIV-positive
women (42.7%) were on antiretroviral therapy at recruitment.
The observed prevalence of malarial and STI/RTI coinfection
TABLE 2
Prevalence of malarial infection and sexually transmitted and repro-
ductive tract infections among first ANC attendees of Nchelenge
District, Zambia
Infection Category
All (N = 1,084)
n (%) 95% Confidence interval
Bacterial vaginosis Normal 375 (34.7) 31.8–37.5
Intermediate 184 (17.0) 14.9–19.4
BV 524 (48.3) 45.2–51.2
Missing* 1
Trichomoniasis Positive 269 (24.8) 22.3–27.5
Missing* 1
Chlamydia Positive 56 (5.2) 3.9–6.7
Missing* 1
Gonorrhea Positive 34 (3.1) 2.2–4.4
Missing* 1
Confirmed syphilis Positive 76 (7.1) 5.6–8.7
Missing* 7
Malarial infection Positive 621 (57.8) 54.8–60.7
Missing* 10
Composite STI Positive 374 (34.5) 31.7–37.4
Missing* 1
STI/RTI Positive 702 (64.8) 61.7–67.4
Missing* 1
STI/RTI = sexually transmitted and reproductive tract infection.
*Missing values are only presented as numbers and were not included in the calculation
of percentage. Some values were missing due to missing samples.
TABLE 1
Characteristics of pregnant women at their first antenatal care visit
Characteristics All pregnant women, n (%)
Total 1,084
Recruitment site
Kashikishi 746 (68.8)
Nchelenge 338 (31.2)
Age
Median (IQR) 25 (20–30)
Marital status
Single 203 (18.7)
Married 873 (80.6)
Separated/divorced/widowed 8 (0.7)
Gravidity
Primigravidae 261 (24.1)
Secundigravidae 165 (15.2)
Multigravidae 658 (60.7)
Years of schooling
0–6 years 425 (39.2)
7 years and above 659 (60.8)
Bed-net ownership
No 550 (50.7)
Yes 534 (49.3)
Net usage on previous night
No 665 (61.5)
Yes 416 (38.5)
Missing* 3
IRS in past 1 year
No 665 (61.5)
Yes 416 (38.5)
Missing* 51
Wealth index
Lowest 217 (20.1)
Second 220 (20.3)
Middle 214 (19.8)
Fourth 215 (19.9)
Highest 216 (20.0)
Missing* 2
IQR = interquartile range; IRS = indoor residual spraying; NA = not applicable.
*Missing values are only presented as numbers and were not included in the calculation
of percentages.
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could have been slightly higher than what was observed if
fewer women were on antiretroviral treatment or lower if
more women were undergoing treatment.
Since about 95% of pregnant women in Zambia have at
least one ANC visit41 and the refusal rate in this study was
less than 1%, our results likely reflect the dual burden of
malarial infection and curable STIs/RTIs among all pregnant
women in this setting. Furthermore, inclusion of positive and
negative controls in the molecular diagnosis procedures and
the fact that results obtained from repeat reading and testing
were virtually reproducible enhance the validity of the dual
burden of malarial infection and STI/RTI among pregnant
women in this population.
Quantifying the frequency of malarial and STI/RTI coin-
fection is important in the context of ongoing research for
alternatives to SP for use in IPTp. Our study provides evi-
dence in support of antimalarial and antibacterial drug com-
binations that may offer the added benefit of reducing the
burden of curable STIs/RTIs in pregnancy, especially in
resource-poor settings such as where STIs/RTIs are highly
prevalent and routine screening may not be sustainable. Fur-
thermore, up to 50% of stillbirths have been attributed to
untreated maternal syphilis in some areas42,43 and coverage
of syphilis screening of pregnant women during ANC in sub-
Saharan Africa is estimated to be quite low (39.5%).22 In
fact, malaria and syphilis are the two leading infectious
causes of stillbirth in sub-Saharan Africa, implicated in
420,000 stillbirths, or three of every 10 stillbirths, every year.4
Presumably fewer pregnant women with syphilis are given
appropriate treatment; however, the proportion of women
testing positive for syphilis who receive treatment could be
increased by the use of point of care tests rather than laboratory-
based RPR tests as demonstrated in several countries includ-
ing Zambia.44 An integrated solution for the management
of malarial infection and STI/RTI in pregnancy is clearly
needed for the benefit of pregnant women in areas with poor
resources and overlapping prevalence of malarial infection
and STIs/RTIs.
Bed-net use,45,46 parity, and age1 have been known to be
associated with malarial infection. Parity,47,48 the number of
sexual partners,49 and early sexual debut47,49 have been pre-
viously associated with STIs/RTIs among pregnant women.
No association was found between malarial and STI/RTI
coinfection and factors such as parity, age, the number of
sexual partners, early sexual debut, bed-net ownership, bed-
net use, and wealth quintile in this study.
TABLE 4
Multivariate analyses of risk factors for malarial and curable STI/RTI coinfection among first ANC attendees (N = 1,071)
Potential risk factor Category n (%) Adjusted OR P value
Age group ≤ 20 295 (27.5) 1.00 0.149
21–25 304 (28.3) 0.95 (0.52–1.72)
26–30 244 (22.7) 0.83 (0.43–1.61)
≥ 30 231 (21.5) 0.58 (0.30–1.14)
Gravidity Primigravidae 258 (24.1) 1.00 0.681
Secundigravidae 165 (15.4) 0.96 (0.52–1.88)
Multigravidae 648 (60.5) 0.77 (0.41–1.46)
Bed-net ownership No 734 (68.5) 1.00 0.937
Yes 337 (31.5) 0.83 (0.47–1.47)
Bed-net use on previous night No 658 (61.6) 1.00 0.386
Yes 410 (38.4) 0.98 (0.56–1.74)
Missing 3
HIV status Negative 933 (87.1) 1.00 < 0.001
Positive 138 (12.9) 3.93 (1.87–8.27)
Coinfection = infection with malaria parasites and at least one STI/RTI; HIV = human immunodeficiency virus; NA = not applicable; OR = odds ratio; STI/RTI = sexually transmitted and
reproductive tract infection. Only HIV infection was found to be independently associated with malaria and STI/RTI coinfection therefore we did not adjust for any other variable in the final
model. Missing values are only presented as number and were not included in the calculation of percentages and analysis.
TABLE 3
Prevalence of malarial and curable STI/RTI coinfection among pregnant women at first antenatal care visit
Coinfection Category
All women
(N = 1,084) n (%)
HIV uninfected
(N = 941) n (%)
HIV infected
(N = 143) n (%)
95% CI for
difference P value†
Malarial infection and all STIs/RTIs
Coinfection 414 (38.7) 345 (37.0) 69 (50.0) 3.0–20.3 0.003
Malaria only 202 (18.9) 182 (19.5) 20 (14.5) −1.7–10.8 0.154
STI/RTI only 278 (26.0) 237 (25.4) 41 (29.7) −3.9–11.8 0.271
No infection 177 (16.4) 169 (18.1) 8 (5.8) 6.8–16.8 < 0.001
Missing* 13 8 5
Malarial infection and confirmed syphilis Yes 43 (4.0) 31 (3.3) 12 (8.8) 1.3–10.9 0.002
Missing* 12 6 5
Malarial infection and Chlamydia Yes 37 (3.4) 30 (3.2) 7 (5.1) −1.1–6.7 0.263
Missing* 11 6 5
Malarial infection and gonorrhea Yes 22 (2.1) 17 (1.8) 5 (3.6) −0.6–6.2 0.162
Missing* 11 6 5
Malarial infection and trichomoniasis Yes 164 (15.3) 142 (15.2) 22 (15.9) −5.3–7.4 0.818
Missing* 11 6 5
Malarial infection and bacterial vaginosis Yes 313 (29.2) 250 (26.8) 63 (45.7) 9.1–26.1 < 0.001
No Missing* 14 9 5
CI = confidence interval; HIV = human immunodeficiency virus; STI/RTI = sexually transmitted and reproductive tract infection.
*Missing values are only presented as numbers and were not included in the calculation of percentage. Some values were missing due to missing samples.
†P value for two-sample test of proportions.
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HIV-infected women were at a higher risk of malarial
infection and STIs/RTIs. However, as previously reported,27
the sample size was not large enough to conclude that the
increased risk of malarial infection among HIV-infected
women was statistically significant. Infection with HIV has
been associated with both malarial infection50,51 and curable
STIs/RTIs.52,53 It is, therefore, not a surprise finding that
HIV was a risk factor for malarial and STI/RTI coinfection
in our study.
The fact that HIV was strongly associated with malarial
and STI/RTI coinfection among pregnant women on their
first ANC visit highlights the importance of treatment and
prevention of these infections in pregnant HIV-infected
women. In areas where malaria parasites have lost sensitivity
to SP, alternative therapies that combine a broad-spectrum
antibiotic with an efficacious antimalarial should be investi-
gated. One possible combination would involve azithromycin
plus dihydroartemisinin–piperaquine. Azithromycin is effica-
cious against T. pallidum, C. trachomatis and N. gonorrhoea
and may offer some protection against T. vaginalis and
Gardnerella vaginalis, a bacterium that is commonly impli-
cated in bacterial vaginosis.54 Azithromycin is efficacious
against Plasmodium vivax, but needs a potent antimalarial
partner drug to clear P. falciparum.55 Dihydroartemisinin–
piperaquine has been shown to be an efficacious antimalarial
and potential replacement for SP as IPTp.56,57 Therefore,
dihydroartemisinin–piperaquine plus azithromycin could be
a good replacement for SP as IPTp.
Clinicians and staff involved in the provision of ANC ser-
vices also need to be proactive in the management of these
infections, especially in HIV-infected women. Moreover,
the importance of community education on the ways that
malarial infection, HIV, and STI/RTIs can be prevented can-
not be overemphasized.
The lack of association between infections and adverse
birth outcome could partially be attributed to the interven-
tions in the ANC package including IPTp-SP, iron and folic
acid supplementation, and syphilis treatment. Administration
of IPTp-SP reduces the adverse effects of malarial infection
in pregnancy including third trimester maternal anemia, pla-
cental parasitemia, and the incidence of low birth weight.58–61
In this study, IPTp-SP coverage was high, with 99% of women
who were followed to delivery receiving at least one dose of
IPTp-SP during the pregnancy duration. Furthermore, studies
have suggested that SP could offer additional protection
against infections other than malarial infection resulting in
the protective effect against adverse birth outcome, which
becomes more apparent in areas where parasites have
lost sensitivity.26,56
Diagnosis of infections was limited to the first ANC visit
and women were classified as infected or uninfected based
on results from the screening done at first ANC. This poten-
tially may have resulted in the misclassification of individuals
who were classified as uninfected but acquired an infection
later in pregnancy and which may have resulted in the reduc-
tion in the strength of association between infection and
adverse birth outcome. A second screening later in preg-
nancy is recommended in future studies.
The loss to follow-up in this study was much higher than
expected mainly due to unforeseen interruptions in transpor-
tation during the follow-up to delivery period. Additional
factors may be related to myths and traditional beliefs
among residents of this district that influence birthing prac-
tices and cause women to prefer delivery at home in seclu-
sion or away from their home villages.62
Given the high prevalence of malarial infection, STIs/RTIs
and their coinfection in pregnancy alternatives to SP that
address the dual burden of malarial infection and curable
STIs/RTIs should be prioritized.
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